Items where authors include "Ferguson, T.A."

Jump to: Article
Number of items: 5.

Article

Lovett, A., Chary, S., Babu, S. et al. (15 more authors) (2025) Serious neurologic adverse events in Tofersen clinical trials for amyotrophic lateral sclerosis. Muscle & Nerve, 71 (6). pp. 1006-1015. ISSN 0148-639X

van den Berg, L.H., Rothstein, J.D., Shaw, P.J. orcid.org/0000-0002-8925-2567 et al. (26 more authors) (2024) Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study. The Lancet Neurology, 23 (9). pp. 901-912. ISSN 1474-4422

Miller, T.M., Cudkowicz, M.E., Genge, A. et al. (23 more authors) (2022) Trial of antisense oligonucleotide tofersen for SOD1 ALS. New England Journal of Medicine, 387 (12). pp. 1099-1110. ISSN 0028-4793

Miller, T., Cudkowicz, M., Shaw, P.J. orcid.org/0000-0002-8925-2567 et al. (28 more authors) (2020) Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 383 (2). pp. 109-119. ISSN 0028-4793

van Eijk, R.P.A., Nikolakopoulos, S., Roes, K.C.B. et al. (7 more authors) (2019) Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials. Journal of Neurology, Neurosurgery & Psychiatry, 90 (12). pp. 1331-1337. ISSN 0022-3050

This list was generated on Mon Oct 6 19:35:32 2025 BST.